Industrial Technology Research Institute

Megapro Biomedical Co., Ltd.

Kyungpook National University Industry-academic Cooperation Foundation

Ming-Cheng Wei

Shian-Jy Jassy Wang

Yuan-Hung Hsu

Chih-Lung Chen

Wen-Yuan Hsieh

Chia-Wen Huang

Ya-Chin Lo

Hsiang-Fa Liang

Chih-Peng Liu

Maggie J M Lu

Hsiang-Wen Tseng

Jhih-Yun Jian

Li-Wen Chang

Jui-Hsiang Chen

In San Kim

Chia-Mu Tu

Maggie Lu

Byung Heon Lee

Min-Ying Lin

Chun-Min Liu

Yi-Ting Hsieh

Shuen-Hsiang Chou

Shih-Ta Chen

Tse-Min Teng

Yi-Man Chou

Yi-ju Ko

Maggie Jm Lu

A biocompatible magnetic material containing an iron oxide nanoparticle and one or more biocompatible polymers, each having formula (I) below, covalently bonded to the iron oxide nanoparticle: in which each of variables R, L, x, and y is defined herein, the biocompatible magnetic material contains 4-15% Fe(II) ions relative to the total iron ions. Also disclosed in a method of preparing the biocompatible magnetic material.

Biocompatible magnetic materials

A pharmaceutical composition containing a mixed polymeric micelle and a drug enclosed in the micelle, in which the mixed polymeric micelle, 1 to 1000 nm in size, includes an amphiphilic block copolymer and a lipopolymer. Also disclosed are preparation of the pharmaceutical composition and use thereof for treating cancer.

Pharmaceutical compositions containing mixed polymeric micelles

Disclosed is an intralymphatic delivery method for treating lymphatic cancer using hyaluronan nanoparticles. These nanoparticles include a hyaluronic acid derivative and a platinum compound. The hyaluronan derivative includes hyaluronic acid, modified histidine and optionally one or more of a polymer or a C-Calkyl. The hyaluronic acid derivative may include linking group(s) that connect the polymer or the C-Calkyl to the hyaluronic acid. The platinum compound includes dichloro(1,2-diaminocyclohexane) platinum (DACHPt), cisplatin and oxaliplatin. This intralymphatic delivery method offers significant advantages for the use of platinum medicines in treating lymphatic cancer.

Intralymphatic delivery of hyaluronan nanoparticle for cancer metastasis

The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors. Therefore, the liposome which contains anticancer drugs labeled with IL4Pep peptides of the present invention can be applied, as the target-aiming drug delivery system, effectively to the diagnosis and treatment of cancers.

Target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and manufacturing method thereof

The disclosure provides a biomedical composition, including: a hyaluronic acid; a modified histidine; and a polymer or C-Calkane, wherein the modified histidine and the polymer or C-Calkane are grafted to at least one primary hydroxyl group of the hyaluronic acid to allow the hyaluronic acid to form a hyaluronic acid derivative, wherein a graft ratio of the modified histidine is about 1-100%, and a graft ratio of the polymer or C-Calkane is about 0-40%.

Biomedical composition

Growing community of inventors

Taoyuan, Taiwan

Ming-Cheng Wei